BIT Capital GmbH Invests $528,000 in Kiniksa Pharmaceuticals International, plc $KNSA

BIT Capital GmbH purchased a new position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 12,800 shares of the company’s stock, valued at approximately $528,000.

Several other large investors also recently modified their holdings of the company. Amundi bought a new stake in Kiniksa Pharmaceuticals International during the first quarter valued at about $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Kiniksa Pharmaceuticals International by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after acquiring an additional 1,002 shares in the last quarter. Millennium Management LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after acquiring an additional 67,452 shares in the last quarter. Creative Planning purchased a new position in shares of Kiniksa Pharmaceuticals International in the second quarter valued at about $358,000. Finally, Quantbot Technologies LP purchased a new position in shares of Kiniksa Pharmaceuticals International in the second quarter valued at about $43,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA stock opened at $48.42 on Friday. The firm has a market capitalization of $3.73 billion, a price-to-earnings ratio of 53.80 and a beta of 0.12. The business has a fifty day moving average of $50.18 and a 200 day moving average of $45.64. Kiniksa Pharmaceuticals International, plc has a 1 year low of $26.27 and a 1 year high of $59.87.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. The company had revenue of $214.27 million during the quarter, compared to analyst estimates of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The firm’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the business posted $0.11 EPS. As a group, equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.24 earnings per share for the current year.

Insider Activity

In other news, insider John F. Paolini sold 58,424 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the sale, the insider directly owned 65,623 shares in the company, valued at $3,524,611.33. This trade represents a 47.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 48,565 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $54.02, for a total value of $2,623,481.30. Following the transaction, the chief executive officer directly owned 48,565 shares of the company’s stock, valued at $2,623,481.30. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 653,301 shares of company stock worth $34,046,073. 51.98% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

KNSA has been the topic of a number of research analyst reports. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Monday, May 4th. Weiss Ratings upgraded Kiniksa Pharmaceuticals International from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, May 6th. Canaccord Genuity Group upped their price objective on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Wells Fargo & Company upped their target price on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. Finally, Wedbush upped their target price on Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the company an “outperform” rating in a research note on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $60.86.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.